Exact Sciences' Oncotype DX Breast Recurrence Score test has now been used by more than 2,000,000 patients worldwide. The test is widely used to guide individualized breast cancer treatment and help ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

Enhancing coagulopathy management in cancer patients: A quality initiative in thromboelastography interpretation for internal medicine and emergency medicine residents. This is an ASCO Meeting ...

—For certain older patients with low-genomic-risk, early-stage breast cancer, the findings from a new study suggest that some of them may be able to forgo either radiotherapy or endocrine therapy ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American ...